Urapidil CAS：34661-75-1

English Name: urapidil

CAS No.: 34661-75-1

Molecular formula: c20h29n5o3

Molecular weight: 387.48

EINECS No.: 252-130-4

Clinical application:

1. All kinds of hypertension

(1) The effect of URA on essential hypertension is significant, and the effect of URA on reducing systolic blood pressure is more obvious, the impact on heart rate is minimal, the incidence of adverse reactions is low, and patients can tolerate it.

(2) SBP, DBP and HR of patients with severe hypertension after URA were significantly lower than those before URA. Compared with sodium nitroprusside, nitroglycerin and phentolamine, URA has the greatest advantage.

(3) The antihypertensive effect of URA is rapid and effective for hypertension caused by various reasons. The symptoms of URA group were improved well, and there were no side effects such as orthostatic hypotension, flushing and palpitation in phentolamine group.

(4) Pulmonary hypertension α 1 receptor is widely present in the pulmonary vascular bed and blocked by URA α In order to maintain or increase arterial partial pressure, it is necessary to reduce pulmonary arterial pressure, avoid vasodilation in hypoxic area, and not aggravate functional arteriovenous shunt. The results showed that the total effective rate of URA in the treatment of pulmonary hypertension, heart failure and pulmonary heart disease was 91.66%, P (O 2) increased by 25.31%, mean pulmonary artery pressure and pulmonary capillary incarcerated pressure decreased significantly, decreased by 28.74% and 35.62% respectively. At the same time, the product of systolic blood pressure and heart rate also decreased, reflecting the decrease of myocardial oxygen consumption, which is conducive to myocardial protection.

2. All kinds of heart failure

(1) Acute left heart failure was treated with ura25 mg and normal saline 10 ml, IV, 5 min. After that, ura112.5mg was added with 500ml 5% glucose for intravenous drip. Results URA significantly reduced SBP, DBP and HR, and the product of SBP and HR in patients with acute left heart failure. The blood pressure decreased significantly from 5 to 15 minutes after administration, and reached the lowest point at 60 minutes. Compared with before administration, SBP and DBP decreased by 26.8% and 24.6% respectively. The left ventricular systolic function was improved significantly. It has been reported that URA is superior to nitroglycerin in the treatment of acute left heart failure. The total effective rate of URA was 97% in 69 patients and 80% in nitroglycerin. The side effects of URA were less.

(2) Patients with congestive heart failure (CHF) were treated with ura12.5-25mg + 20ml normal saline, IV for 3-5min, followed by 50-100mg URA + 250-500ml 5% glucose. Results the effective rate of URA in improving heart function of patients with congestive heart failure was 92%, and the clinical symptoms were significantly improved. At the same time, URA directly dilated renal vessels, increased renal vascular perfusion and improved renal function, so that the blood and urine after heart failure was corrected β 2-mg decreased.